{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:58:07Z","timestamp":1787029087006,"version":"build-2736575974"},"reference-count":254,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.autrev.2022.103142","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T20:21:26Z","timestamp":1658002886000},"page":"103142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Alarmins in autoimmune diseases"],"prefix":"10.1016","volume":"21","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Andrea","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Claudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.autrev.2022.103142_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.autrev.2022.103142_bb0010","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"10.1016\/j.autrev.2022.103142_bb0015","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.3390\/ijms22169039","article-title":"Involvement of alarmins in the pathogenesis and progression of multiple myeloma","volume":"22","author":"Murdaca","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103142_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fcimb.2012.00168","article-title":"Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination","volume":"2","author":"Jounai","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.autrev.2022.103142_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2016.00159","article-title":"Extracellular HSPs: the complicated roles of extracellular hsps in immunity","volume":"7","author":"Calderwood","year":"2016","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.156","article-title":"Many faces of DAMPs in cancer therapy","volume":"4","author":"Krysko","year":"2013","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/JLB.3MIR1118-443R","article-title":"Extracellular CIRP (eCIRP) and inflammation","volume":"106","author":"Aziz","year":"2019","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2022.103142_bb0040","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3389\/fimmu.2019.02536","article-title":"DAMPs and NETs in Sepsis","volume":"10","author":"Denning","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/07853890.2021.1921252","article-title":"Alarmins, COVID-19 and comorbidities","volume":"53","author":"Di Salvo","year":"2021","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0050","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40291-020-00460-z","article-title":"Use of DAMPs and SAMPs as therapeutic targets or therapeutics: a note of caution","volume":"24","author":"Land","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.autrev.2022.103142_bb0060","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2020.01057","article-title":"HMGB1 in systemic lupus erythematosus","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.autrev.2010.05.015","article-title":"HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development","volume":"9","author":"Abdulahad","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103142_bb0070","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3389\/fimmu.2019.01561","article-title":"Johnny on the spot-chronic inflammation is driven by HMGB1","volume":"10","author":"Gorgulho","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/iid3.370","article-title":"The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic","volume":"9","author":"Li","year":"2021","journal-title":"Immun Inflamm Dis"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0080","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.11028","article-title":"High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis","volume":"48","author":"Pullerits","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0085","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.11161","article-title":"Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity","volume":"48","author":"Kokkola","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0090","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/art.27590","article-title":"Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model","volume":"62","author":"Ostberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103142_bb0095","article-title":"Association of serum\/plasma high mobility group box 1 with autoimmune diseases: a systematic review and meta-analysis","volume":"97","author":"Zhu","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2022.103142_bb0100","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.pain.2014.06.007","article-title":"Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis","volume":"155","author":"Agalave","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.autrev.2022.103142_bb0105","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3389\/fimmu.2018.02118","article-title":"Redox-mediated mechanisms fuel monocyte responses to CXCL12\/HMGB1 in active rheumatoid arthritis","volume":"9","author":"Cecchinato","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12974-015-0269-9","article-title":"Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis","volume":"12","author":"Malhotra","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2022.103142_bb0115","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1189\/jlb.1207844","article-title":"Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis","volume":"84","author":"Andersson","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0120","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s12551-018-0471-y","article-title":"S100 proteins as therapeutic targets","volume":"10","author":"Bresnick","year":"2018","journal-title":"Biophys Rev"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0125","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1172\/JCI89867","article-title":"Autoinhibitory regulation of S100A8\/S100A9 alarmin activity locally restricts sterile inflammation","volume":"128","author":"Vogl","year":"2018","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm.2150","article-title":"The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells","volume":"16","author":"Loser","year":"2010","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/path.2394","article-title":"Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease","volume":"216","author":"Foell","year":"2008","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-018-1584-1","article-title":"Fc\u03b3 receptor-mediated influx of S100A8\/A9-producing neutrophils as inducer of bone erosion during antigen-induced arthritis","volume":"2;20","author":"Di Ceglie","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103142_bb0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1749-6632.2009.04622.x","article-title":"Defensins in systemic lupus erythematosus","volume":"1173","author":"Froy","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s42358-020-00156-2","article-title":"Serum defensin levels in patients with systemic sclerosis","volume":"60","author":"Gedik","year":"2020","journal-title":"Adv Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2010.01558.x","article-title":"Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors","volume":"86","author":"Allegra","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2022.103142_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/jaut.1993.1041","article-title":"Elevated levels of the 90 kD heat shock protein in patients with systemic lupus erythematosus are dependent upon enhanced transcription of the hsp90 beta gene","volume":"6","author":"Twomey","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103142_bb0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jaut.2001.0549","article-title":"Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90","volume":"17","author":"Ripley","year":"2001","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103142_bb0170","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/eji.201445293","article-title":"Heat shock protein 90 associates with toll-like receptors 7\/9 and mediates self-nucleic acid recognition in SLE","volume":"45","author":"Saito","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2016.00201","article-title":"Spatiotemporal regulation of Hsp90-ligand complex leads to immune activation","volume":"7","author":"Tamura","year":"2016","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0180","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.4049\/jimmunol.154.3.1432","article-title":"Balance of IL-1 receptor antagonist\/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL 10","volume":"154","author":"Chomarat","year":"1995","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and in-duces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0200","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.24305","article-title":"Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis","volume":"60","author":"Palmer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren\u2019s syndrome","volume":"20","author":"Soyfoo","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0215","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","article-title":"Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis","volume":"72","author":"Terras","year":"2013","journal-title":"Ann Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0225","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00393-016-0202-3","article-title":"Elevated serum levels of interleukin-1\u03b2 and interleukin-33 in patients with systemic sclerosis in Chinese population","volume":"77","author":"Zhang","year":"2018","journal-title":"Z Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0235","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","article-title":"Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels","volume":"34","author":"Vettori","year":"2014","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0240","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/sji.12317","article-title":"Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis","volume":"82","author":"Wagner","year":"2015","journal-title":"Scand J Immunol"},{"issue":"Suppl. 54","key":"10.1016\/j.autrev.2022.103142_bb0245","first-page":"S84","article-title":"Pathogenesis of systemic lupus erythematosus (SLE)","volume":"29","author":"Conti","year":"2012","journal-title":"G Ital Nefrol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0250","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.4049\/jimmunol.181.6.4240","article-title":"High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine","volume":"181","author":"Liu","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0255","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00296-010-1636-6","article-title":"Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-\u03b1 and TNF-\u03b1 in systemic lupus erythematosus","volume":"32","author":"Ma","year":"2012","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0260","doi-asserted-by":"crossref","first-page":"R184","DOI":"10.1186\/ar4015","article-title":"Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations","volume":"14","author":"Abdulahad","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0265","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1002\/jcp.29379","article-title":"HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis","volume":"235","author":"Feng","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.autrev.2022.103142_bb0270","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/946748","article-title":"HMGB1 promotes systemic lupus erythematosus by enhancing macrophage inflammatory response","volume":"2015","author":"Lu","year":"2015","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0275","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1084\/jem.20180776","article-title":"Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors","volume":"1;215","author":"Nestor","year":"2018","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.2011.02432.x","article-title":"High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus","volume":"270","author":"Urbonaviciute","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2022.103142_bb0285","article-title":"Role of hsp90 in systemic lupus erythematosus and its clinical relevance","volume":"2012","author":"Shukla","year":"2012","journal-title":"Autoimmune Dis"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0290","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/1744666X.2013.814428","article-title":"The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10238-010-0116-3","article-title":"High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway","volume":"11","author":"Guo","year":"2011","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0300","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-3083.2012.02759.x","article-title":"HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with rheumatoid arthritis","volume":"76","author":"He","year":"2012","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/295081","article-title":"Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis","volume":"2012","author":"Shi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0310","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/eji.201444908","article-title":"HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1\u03b1 activation","volume":"45","author":"Park","year":"2015","journal-title":"Eur J Immunol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103142_bb0315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11010-016-2783-1","article-title":"Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression","volume":"420","author":"Li","year":"2016","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0320","first-page":"49","article-title":"Calprotectin in rheumatoid arthritis\u202f: association with disease activity in a cross-sectional and a longitudinal cohort","volume":"17","author":"Garc\u00eda-Arias","year":"2013","journal-title":"Mol DiagnTher"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0325","first-page":"2239","article-title":"Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants","volume":"54","author":"Inciarte-Mundo","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103142_bb0330","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00365513.2017.1413591","article-title":"Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate","volume":"78","author":"Nielsen","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0335","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/acr.22795","article-title":"Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors","volume":"68","author":"Inciarte-Mundo","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000654","article-title":"Predictive value of serum calprotectin (S100A8\/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis","volume":"4","author":"Tweehuysen","year":"2018","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0345","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12870","article-title":"NETs analysed by novel calprotectin-based assays in blood donors and patients with multiple myeloma or rheumatoid arthritis: A pilot study","volume":"91","author":"Fagerhol","year":"2020","journal-title":"Scand J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0350","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acr2.11309","article-title":"Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years","volume":"3","author":"Bettner","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0355","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12192-015-0578-z","article-title":"Analysis of serum heat shock protein 70 (HSPA1A) concentrations for diagnosis and disease activity monitoring in patients with rheumatoid arthritis","volume":"20","author":"Najafizadeh","year":"2015","journal-title":"Cell Stress Chaperones"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0360","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12192-016-0698-0","article-title":"APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+T cells from rheumatoid arthritis patients","volume":"21","author":"Barber\u00e1","year":"2016","journal-title":"Cell Stress Chaperones"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0365","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/1756-185X.13316","article-title":"Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis","volume":"21","author":"Chen","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103142_bb0370","article-title":"Chemical inhibition of HSP90 inhibits TNF-\u03b1 mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes","author":"Yang","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.autrev.2022.103142_bb0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/OARRR.S162512","article-title":"Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"10","author":"Ulusoy","year":"2018","journal-title":"Open Access Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0380","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12192-018-0951-9","article-title":"Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis","volume":"24","author":"Mantej","year":"2019","journal-title":"Cell Stress Chaperones"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0385","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3899\/jrheum.100184","article-title":"Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis","volume":"37","author":"Mu","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103142_bb0390","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0395","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00296-011-1854-6","article-title":"Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1\u03b2signaling and a poor clinical response","volume":"32","author":"Matsuyama","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0400","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cyto.2011.12.010","article-title":"Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis","volume":"58","author":"Xiangyang","year":"2012","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0405","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5606\/ArchRheumatol.2018.6753","article-title":"Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis","volume":"33","author":"Choi","year":"2018","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.autrev.2022.103142_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to tnf inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0415","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.20220","article-title":"Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids","volume":"50","author":"Ulfgren","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0420","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1096\/fj.09-144782","article-title":"Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies","volume":"24","author":"Grundtman","year":"2010","journal-title":"FASEB J"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0425","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/annrheumdis-2012-202207","article-title":"TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis","volume":"72","author":"Zong","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103142_bb0430","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.intimp.2016.10.009","article-title":"TLR4-HMGB1 signaling pathway affects the inflammatory reaction of autoimmune myositis by regulating MHC-I","volume":"41","author":"Wan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2022.103142_bb0435","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.expneurol.2015.05.023","article-title":"HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis","volume":"271","author":"Muth","year":"2015","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0440","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10974-015-9411-7","article-title":"HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases","volume":"36","author":"Cseri","year":"2015","journal-title":"J Muscle Res Cell Motil"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161436","article-title":"HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis \/dermatomyositis with interstitial lung disease","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0450","first-page":"1332","article-title":"MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1","volume":"53","author":"Liu","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.autrev.2022.103142_bb0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fcell.2020.00226","article-title":"Aberrant expression of high mobility group box protein 1 in the idiopathic inflammatory myopathies","volume":"8","author":"Day","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0460","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1753425913481820","article-title":"Human \u03b2-defensin-3 correlates with muscle fibre degeneration in idiopathic inflammatory myopathies","volume":"20","author":"G\u00fcttsches","year":"2014","journal-title":"Innate Immun"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0465","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-018-0609-5","article-title":"Elevated \u03b1-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease","volume":"18","author":"Sakamoto","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0304-3940(91)90230-Q","article-title":"Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy","volume":"130","author":"Askanas","year":"1991","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0475","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1212\/WNL.42.2.460","article-title":"Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis","volume":"42","author":"Askanas","year":"1992","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0480","first-page":"31","article-title":"Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis","volume":"141","author":"Askanas","year":"1992","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0485","first-page":"789","article-title":"Ubiquitin expression in inclusion body myositis. An immunohistochemical study","volume":"117","author":"Albrecht","year":"1993","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0490","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0960-8966(93)90021-B","article-title":"Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study","volume":"3","author":"Leclerc","year":"1993","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0495","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF00334447","article-title":"Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis","volume":"85","author":"Bilak","year":"1993","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0500","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/(SICI)1097-4598(199605)19:5<574::AID-MUS4>3.0.CO;2-8","article-title":"Heat-shock protein 90 and ubiquitin: developmental regulation during myogenesis","volume":"19","author":"Bornman","year":"1996","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0505","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0046-8177(97)90002-2","article-title":"Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis","volume":"28","author":"Prayson","year":"1997","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0510","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/01.WNL.0000138574.56908.5D","article-title":"Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers","volume":"63","author":"Fratta","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0515","first-page":"17","article-title":"Sporadic inclusion-body myositis: a proposed key pathogenetic role of the abnormalities of the ubiquitin-proteasome system, and protein misfolding and aggregation","volume":"24","author":"Askanas","year":"2005","journal-title":"Acta Myol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0520","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.38180","article-title":"Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target","volume":"65","author":"Rayavarapu","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2022.103142_bb0525","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0530","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0535","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0540","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.autrev.2022.103142_bb0545","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","article-title":"High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis","volume":"54","author":"Muro","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0550","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12026-018-9006-7","article-title":"Antibodies to small ubiquitin-like modifier activating enzyme are associated with a diagnosis of dermatomyositis: results from an unselected cohort","volume":"66","author":"Peterson","year":"2018","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0555","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/ajd.12659","article-title":"Recalcitrant ulcers associated with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis treated with surgery followed by intravenous immunoglobulin","volume":"59","author":"Lee","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0560","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/bjd.17026","article-title":"Diffuse erythema with \u2018angel wings\u2019 sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis","volume":"179","author":"Inoue","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2022.103142_bb0565","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.16124","article-title":"Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with anti-small ubiquitin-like modifier activating enzyme antibody","author":"Hiraiwa","year":"2022","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0570","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/1756-185X.13593","article-title":"Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease","volume":"22","author":"Gono","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"6S","key":"10.1016\/j.autrev.2022.103142_bb0575","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1097\/RHU.0000000000001721","article-title":"Exercise training attenuates ubiquitin-proteasome pathway and increases the genes related to autophagy on the skeletal muscle of patients with inflammatory myopathies","volume":"27","author":"Borges","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0580","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.54.5.1033","article-title":"AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis","volume":"54","author":"Banwell","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0585","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nmd.2006.08.009","article-title":"AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis","volume":"16","author":"Wojcik","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0590","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2009.174276","article-title":"Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid","volume":"80","author":"Muth","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0595","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ana.410320619","article-title":"Expression of 65-kd heat shock proteins in the inflammatory myopathies","volume":"32","author":"Hohlfeld","year":"1992","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0600","first-page":"1163","article-title":"Expression of the heat shock protein 70 in inflammatory myopathies","volume":"35","author":"Ibi","year":"1995","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.autrev.2022.103142_bb0605","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1749-6632.2009.04812.x","article-title":"A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages","volume":"1173","author":"De Paepe","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0610","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nmd.2011.07.007","article-title":"Heat shock protein families 70 and 90 in Duchenne muscular dystrophy and inflammatory myopathy: balancing muscle protection and destruction","volume":"22","author":"Paepe","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2022.103142_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811045","article-title":"Hsp90 levels in idiopathic inflammatory myopathies and their association with muscle involvement and disease activity: a cross-sectional and longitudinal study","volume":"13","author":"\u0160tork\u00e1nov\u00e1","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0620","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.1780330713","article-title":"Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis","volume":"33","author":"Wolf","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0625","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V","article-title":"Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis","volume":"43","author":"Lundberg","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0630","first-page":"940","article-title":"Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis","volume":"27","author":"Nyberg","year":"2000","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0635","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.10140","volume":"46","author":"Englund","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0640","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0645","first-page":"428","article-title":"Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis","volume":"31","author":"Yuan","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0650","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00296-020-04554-z","article-title":"Interleukin-33\/suppression of tumorigenicity 2 (IL-33\/ST2) axis clinical parameters: a pilot study","volume":"40","author":"Opinc","year":"2020","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0655","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/jnnp.2005.081810","article-title":"Expression of granulysin in polymyositis and inclusion-body myositis","volume":"77","author":"Ikezoe","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103142_bb0660","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaut.2016.12.003","article-title":"The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis","volume":"78","author":"Lu","year":"2017","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0665","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2022.103142_bb0670","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-015-0587-4","article-title":"High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4","volume":"17","author":"Wang","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2022.103142_bb0675","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.autrev.2015.07.010","article-title":"Emerging role of high mobility group box 1 in ANCA-associated vasculitis","volume":"14","author":"Wang","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103142_bb0680","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-015-0903-z","article-title":"tian, Wang C, et al. High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation","volume":"18","author":"Ma","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb0685","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/jcmm.13065","article-title":"HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vasculitis through enhancing endothelium\u2013neutrophil interactions","volume":"21","author":"Wang","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0690","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/08916934.2019.1696777","article-title":"Effect of high mobility group box 1 on Toll-like receptor 9 in B cells in myeloperoxidase-ANCA-associated vasculitis","volume":"53","author":"Wang","year":"2020","journal-title":"Autoimmunity"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103142_bb0695","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2119\/molmed.2010.00132","article-title":"High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations","volume":"17","author":"Bruchfeld","year":"2011","journal-title":"Mol Med"},{"issue":"11","key":"10.1016\/j.autrev.2022.103142_bb0700","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/acr.22187","article-title":"Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"65","author":"Wang","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0705","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014493","article-title":"Association of serum high mobility group box 1 levels with disease activity and renal involvement in patients with systemic vasculitis","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0710","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar4284","article-title":"Is serum HMGB1 a biomarker in ANCA-associated vasculitis?","volume":"15","author":"de Souza","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0715","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.21873\/invivo.12435","article-title":"Association Between Serum Alarmin Levels and Disease-specific Indices in Patients With Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","volume":"35","author":"Ahn","year":"2021","journal-title":"In Vivo"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0720","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/ard.2009.119172","article-title":"Serum HMGB1 levels are increased in active Wegener\u2019s granulomatosis and differentiate between active forms of ANCA-associated vasculitis","volume":"69","author":"Wibisono","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2022.103142_bb0725","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2010.146456","article-title":"Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"70","author":"Henes","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096067","article-title":"Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis","volume":"9","author":"de Souza","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0735","doi-asserted-by":"crossref","first-page":"118677","DOI":"10.1016\/j.bbamcr.2020.118677","article-title":"Role of S100 proteins in health and disease","volume":"1867","author":"Gonzalez","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Res"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0740","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0745","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000639","article-title":"Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against candida albicans","volume":"5","author":"Urban","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.autrev.2022.103142_bb0755","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3389\/fimmu.2019.02617","article-title":"Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with polyangiitis","volume":"10","author":"Akiyama","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0760","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ki.2013.2","article-title":"Leukocyte and serum S100A8\/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis","volume":"83","author":"Pepper","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205982","article-title":"Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis","volume":"13","author":"Martinez Valenzuela","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103142_bb0770","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13075-017-1429-3","article-title":"Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"19","author":"Ishizaki","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103142_bb0775","article-title":"Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses","author":"Page","year":"2021","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0780","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CNP66315","article-title":"Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis","volume":"66","author":"Komatsuda","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.autrev.2022.103142_bb0785","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fped.2018.00341","article-title":"S100A12 serum levels and PMN counts are elevated in childhood systemic vasculitides especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies","volume":"6","author":"Brown","year":"2018","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0790","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12192-020-01151-8","article-title":"Intense immunostaining of heat shock protein 70 within renal interstitium associates with long-term renal survival in an ANCA-associated vasculitis cohort","volume":"26","author":"Petrakis","year":"2021","journal-title":"Cell Stress Chaperones"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb0795","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1348-0421.2011.00351.x","article-title":"Increased concentrations of antibody against heat shock protein in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody positive microscopic polyangiitis","volume":"55","author":"Komiya","year":"2011","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb0800","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1740-2557-3-4","article-title":"Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study","volume":"3","author":"Slot","year":"2006","journal-title":"J Autoimmune Dis"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103142_bb0805","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-007-8062-x","article-title":"HSP60 and anti-HSP60 antibodies in vasculitis: they are two of a kind","volume":"35","author":"Alard","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"issue":"14","key":"10.1016\/j.autrev.2022.103142_bb0810","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","article-title":"Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production","volume":"114","author":"Choi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103142_bb0815","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vph.2015.07.012","article-title":"IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms","volume":"73","author":"Chalubinski","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.autrev.2022.103142_bb0820","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/603750","article-title":"Increased levels of soluble ST2 in patients with active newly diagnosed ANCA-associated vasculitis","volume":"2015","author":"Hladinova","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"11","key":"10.1016\/j.autrev.2022.103142_bb0825","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00296-019-04364-y","article-title":"Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study","volume":"39","author":"Hoffmann","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103142_bb0830","doi-asserted-by":"crossref","unstructured":"Kotas ME, Dion J, Van Dyken S, et al. A role for IL-33\u2013activated ILC2s in eosinophilic vasculitis. JCI Insight 6(12):e143366. doi:https:\/\/doi.org\/10.1172\/jci.insight.143366.","DOI":"10.1172\/jci.insight.143366"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb0835","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/cea.13209","article-title":"Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis","volume":"48","author":"Tsurikisawa","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0840","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/0394632015617063","article-title":"Clinic manifestations in granulomatosis with polyangiitis","volume":"29","author":"Greco","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"34","key":"10.1016\/j.autrev.2022.103142_bb0845","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.2174\/138161211798357872","article-title":"Interleukin-25: key regulator of inflammatory and autoimmune diseases","volume":"17","author":"Saadoun","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0850","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1165\/rcmb.2015-0038OC","article-title":"IL-17RA signaling in airway inflammation and bronchial hyperreactivity in allergic asthma","volume":"53","author":"Willis","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0855","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2006.04.051","article-title":"IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice","volume":"118","author":"Tamachi","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.autrev.2022.103142_bb0860","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood-2010-02-267542","article-title":"Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome","volume":"116","author":"Terrier","year":"2010","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0865","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.3390\/jcm10122715","article-title":"Chemokine\/cytokine levels correlate with organ involvement in PR3-ANCA-associated vasculitis","volume":"10","author":"M\u00fcller-Deile","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0870","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0002-9440(10)63085-4","article-title":"Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice","volume":"159","author":"Taneda","year":"2001","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0875","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1681\/ASN.2007040395","article-title":"TLR4 links podocytes with the innate immune system to mediate glomerular injury","volume":"19","author":"Banas","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0880","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar4344","article-title":"The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis","volume":"15","author":"Zhang","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0885","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/ar4495","article-title":"Cathelicidin antimicrobial peptide as a serologic marker and potential pathogenic factor in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"16","author":"Gasim","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0890","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40620-016-0336-z","article-title":"Pathogenesis of antimicrobial peptides LL-37 and CpG-ODN in ANCA associated vasculitis","volume":"30","author":"Luan","year":"2017","journal-title":"J Nephrol"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2022.103142_bb0895","article-title":"Beh\u00e7et: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0900","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3346\/jkms.2011.26.5.697","article-title":"Extracellular high-mobility group box 1 is increased in patients with Beh\u00e7et\u2019s disease with intestinal involvement","volume":"26","author":"Ahn","year":"2011","journal-title":"J Korean Med Sci"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0905","first-page":"2151","article-title":"High mobility group box 1 serum levels are increased in Beh\u00e7et\u2019s disease, but not associated with disease activity or disease manifestations","volume":"54","author":"de Souza","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0910","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5021\/ad.2011.23.3.313","article-title":"Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Beh\u00e7et\u2019s disease and its association with disease activity: a pilot study","volume":"23","author":"Han","year":"2011","journal-title":"Ann Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0915","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/00365513.2014.984319","article-title":"Elevated serum levels of calprotectin (MRP8\/MRP14) in patients with Beh\u00e7et\u2019s disease and its association with disease activity and quality of life","volume":"75","author":"Oktayoglu","year":"2015","journal-title":"Scand J Clin Lab Invest"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb0920","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jgh.13530","article-title":"Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Beh\u00e7et\u2019s disease","volume":"32","author":"Kim","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"6 Suppl 115","key":"10.1016\/j.autrev.2022.103142_bb0925","first-page":"90","article-title":"Faecal but not serum calprotectin levels look promising in predicting active disease in Beh\u00e7et\u2019s syndrome patients with gastrointestinal involvement","volume":"36","author":"Esatoglu","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0930","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jbspin.2011.01.012","article-title":"Increased \u03b1-defensin-1 expression in Korean patients with Behcet\u2019s disease","volume":"78","author":"Ahn","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb0935","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.21873\/invivo.11629","article-title":"Enhanced NLRP3 and DEFA1B expression during the active stage of parenchymal neuro-Beh\u00e7et\u2019s disease","volume":"33","author":"Ugurel","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.autrev.2022.103142_bb0940","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejim.2019.02.008","article-title":"Association of systemic beta-defensin-1 and -20G\/A DEFB1 gene polymorphism with Beh\u00e7et\u2019s disease","volume":"65","author":"Kallel","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb0945","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.18295\/squmj.2015.15.04.008","article-title":"Association of higher Defensin \u03b2-4 genomic copy numbers with Beh\u00e7et\u2019s disease in iraqi patients","volume":"15","author":"Hameed","year":"2015","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0950","doi-asserted-by":"crossref","first-page":"1284449","DOI":"10.1080\/20013078.2017.1284449","article-title":"Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Beh\u00e7et\u2019s disease severity","volume":"6","author":"Kahraman","year":"2017","journal-title":"J Extracell Vesicles"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0955","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1067\/mjd.2001.117728","article-title":"HSP 60 expression in mucocutaneous lesions of Beh\u00e7et\u2019s disease","volume":"45","author":"Ergun","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2022.103142_bb0960","article-title":"Innate and adaptive responses to heat shock proteins in Behcet\u2019s disease","volume":"2013","author":"Direskeneli","year":"2013","journal-title":"Genet Res Int"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0965","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tripleo.2010.03.020","article-title":"HSP 60 expression in recurrent oral ulcerations of Beh\u00e7et\u2019s disease","volume":"110","author":"Deniz","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb0970","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","article-title":"Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Beh\u00e7et\u2019s disease","volume":"139","author":"Imamura","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"4 Suppl 50","key":"10.1016\/j.autrev.2022.103142_bb0975","first-page":"S96","article-title":"Serum levels of free heat shock protein 70 and anti-HSP70 are elevated in Beh\u00e7et\u2019s disease","volume":"26","author":"Birtas-Atesoglu","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb0980","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/sji.12045","article-title":"Diagnostic yield of heat shock protein 70 (HSP-70) and anti-HSP-70 in Behcet-induced uveitis","volume":"77","author":"Sahebari","year":"2013","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb0985","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/09273948.2016.1158276","article-title":"Analysis of Th cell-related cytokine production in Beh\u00e7et disease patients with uveitis before and after infliximab treatment","volume":"25","author":"Takeuchi","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2022.103142_bb0990","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2018.03.016","article-title":"Elevated expression of TSLP and IL-33 in Beh\u00e7et\u2019s disease skin lesions: IL-37 alleviate inflammatory effect of TSLP","volume":"192","author":"Kacem","year":"2018","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb0995","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1007\/s10792-020-01530-1","article-title":"O Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet\u2019s disease","volume":"40","author":"Cingu","year":"2020","journal-title":"Int Ophthalmol"},{"issue":"3 Suppl 77","key":"10.1016\/j.autrev.2022.103142_bb1000","first-page":"6","article-title":"Serum IL-33 levels and skin mRNA expression in Beh\u00e7et\u2019s disease","volume":"31","author":"Hamzaoui","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb1005","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","article-title":"Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet\u2019s disease","volume":"28","author":"Kim","year":"2013","journal-title":"J Korean Med Sci"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1010","first-page":"1","article-title":"Serum interleukin-33 in Behcet\u2019s disease: its relation to disease activity and clinical manifestations","volume":"22","author":"Fawzy","year":"2015","journal-title":"Egypt J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/17843286.2017.1314241","article-title":"Investigating the role of IL-33 in the pathogenesis of Beh\u00e7et\u2019s Disease","volume":"72","author":"\u00c7er\u00e7i","year":"2017","journal-title":"Acta Clin Belg"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00296-014-3111-2","article-title":"P Serum IL-33 level and IL-33 gene polymorphisms in Beh\u00e7et\u2019s disease","volume":"35","author":"Koca","year":"2015","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/cmi.2014.31","article-title":"N Increased interleukin 33 in patients with neuro-Behcet\u2019s disease: correlation with MCP-1 and IP-10 chemokines","volume":"11","author":"Hamzaoui","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb1030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2017.00200","article-title":"Cytokine signatures in mucocutaneous and ocular Beh\u00e7et\u2019s disease","volume":"8","author":"Lopalco","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103142_bb1035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.imlet.2019.05.004","article-title":"Th 9 cells in Beh\u00e7et disease: Possible involvement of IL-9 in pulmonary manifestations","volume":"211","author":"Kaabachi","year":"2019","journal-title":"Immunol Lett"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anndiagpath.2012.11.005","article-title":"Immunohistochemical expression of heat shock protein 70 in vitiligo","volume":"17","author":"Abdou","year":"2013","journal-title":"Ann Diagn Pathol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103142_bb1045","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2008.45","article-title":"HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo","volume":"128","author":"Denman","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2022.103142_bb1050","doi-asserted-by":"crossref","first-page":"1608586","DOI":"10.1155\/2021\/1608586","article-title":"Folic acid protects melanocytes from oxidative stress via activation of Nrf2 and inhibition of HMGB1","volume":"2021","author":"Du","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ced.12464","article-title":"Interleukin-33 affects cytokine production by keratinocytes in vitiligo","volume":"40","author":"Li","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1060","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/bjd.15151","article-title":"Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo","volume":"176","author":"Kim","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103142_bb1065","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.jid.2019.03.1148","article-title":"Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous in flammation in vitiligo","volume":"139","author":"Cui","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1684\/ejd.2019.3526","article-title":"Heat shock proteins and psoriasis","volume":"29","author":"Wang","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103142_bb1075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/1523-1747.ep12499953","article-title":"Induction of the 72-kD heat shock protein in organ-cultured normal human skin","volume":"98","author":"Muramatsu","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70 is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb1085","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","article-title":"S100B Is a Potential Disease Activity Marker in Nonsegmental Vitiligo","volume":"137","author":"Speeckaert","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb1090","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jid.2017.03.021","article-title":"S100B: correlation with active vitiligo depigmentation","volume":"137","author":"Birlea","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2022.103142_bb1095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2019.02.019","article-title":"IL-33 contributes to disease severity in Psoriasis-like models of mouse","volume":"119","author":"Duan","year":"2019","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ced.12670","article-title":"Serum IL-33 levels are increased in patients with psoriasis","volume":"41","author":"Mitsui","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05621","article-title":"Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms","volume":"6","author":"Chaowattanapanit","year":"2020","journal-title":"Heliyon."},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb1110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5114\/ada.2021.108926","article-title":"Significance of interleukin-31 (IL-31) gene polymorphisms and IL-31 serum level in psoriasis in correlation with pruritus","volume":"38","author":"Purzycka-Bohdan","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1115","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5858\/2003-127-178-IIRRIN","article-title":"Innate immune-related receptors in normal and psoriatic skin","volume":"127","author":"Curry","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2133.2005.06701.x","article-title":"Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis","volume":"152","author":"Boyman","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2022.103142_bb1125","doi-asserted-by":"crossref","first-page":"8465083","DOI":"10.1155\/2020\/8465083","article-title":"Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris","volume":"2020","author":"Borsky","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdermsci.2013.08.009","article-title":"Serum granulysin as a possible key marker of the activity of alopecia areata","volume":"73","author":"Ono","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb1135","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications","volume":"10","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1140","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1145","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/jocd.13598","article-title":"Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy","volume":"20","author":"Oba","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb1150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: a systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb1155","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1160","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.gene.2013.02.048","article-title":"A functional polymorphism in interleukin-1\u03b1 (IL1A) gene is associated with risk of alopecia areata in Chinese populations","volume":"521","author":"Lu","year":"2013","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/ijt.ijt_18_17","article-title":"Minoxidil downregulates interleukin-1 alpha gene expression in HaCaT cells","volume":"10","author":"Pekmezci","year":"2018","journal-title":"Int J Trichol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103142_bb1170","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jocd.13814","article-title":"Cross talk between oxidative stress and inflammation in alopecia areata","volume":"20","author":"Mustafa","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1175","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5005\/jp-journals-10024-1610","article-title":"Evaluation of interleukin-1\u03b1, interleukin-10, tumor necrosis factor-\u03b1 and transforming growth factor-\u03b2 in the serum of patients with pemphigus vulgaris","volume":"15","author":"Khozeimeh","year":"2014","journal-title":"J Contemp Dent Pract"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0923-1811(98)00074-7","article-title":"Endogenous neutralizing anti-IL-1 alpha autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1","volume":"20","author":"Mizutani","year":"1998","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1185","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/120347549900300306","article-title":"In vitro C3 mRNA expression in Pemphigus vulgaris: complement activation is increased by IL-1alpha and TNF-alpha","volume":"3","author":"Feliciani","year":"1999","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103142_bb1195","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0625.2002.120415.x","article-title":"Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis","volume":"12","author":"Feliciani","year":"2003","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/039463200702000209","article-title":"Tannic acid induces in vitro acantholysis of keratinocytes via IL-1alpha and TNF-alpha","volume":"20","author":"Feliciani","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103142_bb1210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bjd.13716","article-title":"Elevated interleukin-33 and soluble ST2 levels in the sera of patients with pemphigus vulgaris: correlation with clinical and immunological parameters during follow-up","volume":"173","author":"Tirado-S\u00e1nchez","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1215","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14605","article-title":"Does interleukin-33 level correlate with the activity of Pemphigus vulgaris?: A case-control study","volume":"34","author":"Bakr","year":"2021","journal-title":"Dermatol Ther"},{"issue":"20","key":"10.1016\/j.autrev.2022.103142_bb1220","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00018-009-0086-3","article-title":"Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology","volume":"66","author":"Kostenko","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.autrev.2022.103142_bb1225","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2353\/ajpath.2008.080391","article-title":"Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin","volume":"173","author":"Berkowitz","year":"2008","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103142_bb1230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5021\/ad.2017.29.1.121","article-title":"Increased serum high mobility group box 1 (HMGB1) concentration and the altered expression of HMGB1 and its receptor advanced glycation endproducts in pemphigus","volume":"29","author":"Li","year":"2017","journal-title":"Ann Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103142_bb1235","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/ced.13289","article-title":"Antioxidant status of serum bilirubin, uric acid and albumin in pemphigus vulgaris","volume":"43","author":"Li","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103142_bb1240","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1111\/jdv.16730","article-title":"Increased expression of in situ IL-31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL-31 family in the pathogenesis of the disease","volume":"34","author":"Morais","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2022.103142_bb1245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.trre.2011.07.001","article-title":"Emerging role of innate immunity in organ transplantation part III: the quest for transplant tolerance via prevention of oxidative allograft injury and its consequences","volume":"26","author":"Land","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.autrev.2022.103142_bb1250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20140467","article-title":"Pound the alarm: danger signals in rheumatic diseases","volume":"128","author":"O\u2019Reilly","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.autrev.2022.103142_bb1255","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14728222.2018.1439924","article-title":"Extracellular HMGB1 as a therapeutic target in inflammatory diseases","volume":"22","author":"Andersson","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.autrev.2022.103142_bb1260","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1021\/acs.jmedchem.7b01136","article-title":"High mobility group box-1 (HMGb1): current wisdom and advancement as a potential drug target","volume":"61","author":"VanPatten","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2022.103142_bb1265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191676","article-title":"Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb\u00ae sorbent porous polymer beads","volume":"13","author":"Gruda","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2022.103142_bb1270","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40291-020-00460-z","article-title":"Use of DAMPs and SAMPs as therapeutic targets or therapeutics: a note of caution","volume":"24","author":"Land","year":"2020","journal-title":"Mol Diagn Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:33Z","timestamp":1761600453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":254,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1568997222001124"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103142","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alarmins in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103142"}}